Fresenius Medical Care AG (NYSE:FMS) Forecasted to Post Q1 2026 Earnings of $0.42 Per Share

Fresenius Medical Care AG (NYSE:FMS) – Equities research analysts at Zacks Research upped their Q1 2026 earnings per share estimates for Fresenius Medical Care in a report issued on Wednesday, October 2nd. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will earn $0.42 per share for the quarter, up from their prior estimate of $0.41. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q2 2026 earnings at $0.43 EPS and FY2026 earnings at $1.99 EPS.

Other equities analysts have also issued research reports about the stock. Truist Financial boosted their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday. StockNews.com initiated coverage on Fresenius Medical Care in a research note on Tuesday. They issued a “strong-buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Fresenius Medical Care presently has a consensus rating of “Hold” and an average target price of $23.00.

Fresenius Medical Care Stock Down 2.9 %

Shares of NYSE:FMS opened at $20.00 on Monday. The company has a 50 day moving average price of $19.78 and a two-hundred day moving average price of $20.02. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. The company has a market capitalization of $11.74 billion, a PE ratio of 22.47, a PEG ratio of 1.08 and a beta of 0.91. Fresenius Medical Care has a 52 week low of $16.37 and a 52 week high of $22.76.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting analysts’ consensus estimates of $0.38. The company had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in shares of Fresenius Medical Care by 21.8% during the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after acquiring an additional 758 shares in the last quarter. Wulff Hansen & CO. increased its holdings in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after purchasing an additional 325,439 shares in the last quarter. QRG Capital Management Inc. raised its stake in shares of Fresenius Medical Care by 19.5% in the 1st quarter. QRG Capital Management Inc. now owns 54,363 shares of the company’s stock valued at $1,048,000 after purchasing an additional 8,870 shares during the period. SG Americas Securities LLC raised its stake in shares of Fresenius Medical Care by 50.0% in the 1st quarter. SG Americas Securities LLC now owns 15,228 shares of the company’s stock valued at $294,000 after purchasing an additional 5,078 shares during the period. Finally, Legacy Wealth Asset Management LLC bought a new stake in shares of Fresenius Medical Care in the first quarter valued at about $584,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.